Abstract
The combination of intracytoplasmic sperm injection (ICSI) with oocyte activation has resulted in pregnancies and the birth of healthy babies for patients with repeated fertilization failure after ICSI. However, the introduction oocyte activation into human assisted reproductive technology faces significant risk because every mammal oocyte undergoing oocyte activation has the possibility of becoming parthenote, which is not capable of developing to term due to genomic imprinting. Some genomic imprinting genes, such as insulin-like growth factor II (IGF-II) that is expressed from the paternal allele play a key role in mammalian growth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
